Endometrial Cancer
Conditions
Keywords
Dostarlimab, Radiation, 20-491
Brief summary
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Interventions
RADIATIONIntensity modulated radiation therapy (IMRT)
To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
DRUGDostarlimab
IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.
RADIATIONHypofractionated IMRT
Treatment will consist of short-course, hypofractionated IMRT to deliver 25 Gy to the vaginal cuff and pelvic lymph nodes in 5 daily fractions over one week.
Sponsors
Memorial Sloan Kettering Cancer Center
Tesaro, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase II stud y Adjuvant Checkpoint Blockade Plus Radiation in Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSIH) Endometrial Cancer with safety run-in of adjuvant checkpoint blockade with radiation in women with Stage III-IVA, dMMR/MSI-H endometrial cancer
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * ECOG performance status 0-1 * Endometrial cancer: all histologies (submission of pathology report is required for all patients who underwent surgery outside of MSK) * MMR-D or MSI-H or POLE-mutated (submission of report\[s\] required for. patients who underwent testing outside of MSK POLE-mutated endometrial cancers will be included regardless of MMR/MSI status and limited to up to 3 patients per group. * Patients with hypermethylation of MMR gene promoters (MLH1, MSH2, MSH6 or PMS2) will be included * POLE-mutated endometrial cancers will be included * Must have undergone a complete surgical staging and have stage III/IVA disease. * Patients with measurable disease (RECIST 1.1) after surgery are NOT eligible. * PatienSurgery completed between 3 weeks and 12 weeks (inclusive) before cycle 1 day 1 of therapy, and must have adequately recovered from surgery and any complications of surgery.ts with isolated tumor cells in lymph nodes found on surgery will be counted as clinical stage III disease * Surgery completed between 3 weeks and 12 weeks (inclusive) before cycle 1 day 1 of therapy, and must have adequately recovered from surgery and any complications of surgery. * Has a negative serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential, and agrees use an adequate method of contraception from screening through 150 days after the last dose of study treatment, or is of nonchildbearing potential. Nonchildbearing potential is defined as follows (by other than medical reasons): °≥45 years of age and has not had menses for \>1 year * Patients who have been amenorrhoeic for \<2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use an adequate birth control method throughout the study, starting with the screening visit through 150 days after the last dose of study treatment. See list of acceptable birth control methods. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient. * Participant must agree to not breastfeed during the study or for 150 days after the last dose of study treatment. * Demonstrate adequate organ function as defined below. All screening labs should be performed within 14 days of treatment initiation. * Absolute neutrophil count (ANC) ≥1,500 /mcL * Platelets ≥100,000 / mcL * Hemoglobin ≥9 g/dL * Creatinine Clearance GFR ≥ 45 * Serum total bilirubin ≤ 1.5 X ULN (patients with known Gilbert's disease Serum total bilirubin who have bilirubin level ≤ 3 x ULN may be enrolled) * AST and ALT 3 ULN OR ≤ 5 X ULN for subjects with liver metastases * TSH within normal limits. If TSH is not within normal range despite no symptoms of thyroid dysfunction, normal free T4 level is required.
Exclusion criteria
* Has had prior chemotherapy, targeted therapy, or investigational therapy for endometrial cancer. °Patients who have received prior chemotherapy, targeted therapy, or other investigational therapies for other cancers and are in remission/cured may be included at the discretion of the treating investigator in consultation with the study PI. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent for endometrial cancer. * Unfit for Radiation Therapy due to the following: * Has had radiation therapy encompassing \>20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to Day 1 of protocol therapy. * Patients with a prior history of pelvic radiation * Patients with a prior known history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula. * Any hematological abnormality or disorder that would be a contraindication to radiation per the treating physician. * Hypersensitivity to Dostarlimab or any of its excipients * Patients with diagnosis of immunodeficiency or patients receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled. * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. * Total systemic steroid dose cannot exceed an equivalent of 10mg of prednisone daily and dose must be stable for at least 4 weeks prior to initiating protocol therapy * Has active TB (Bacillus tuberculosis) * Has evidence of active, non-infectious pneumonitis. * Has history of interstitial lung disease * Has an active infection requiring systemic therapy with intravenous antibiotics * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, and superior vena cava syndrome. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation. * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease; systemic lupus erythematosus; Wegener syndrome \[granulomatosis with polyangiitis\]; myasthenia gravis; Graves' disease; rheumatoid arthritis, hypophysitis, uveitis) within the past 3 years prior to the start of treatment or patients requiring immunosuppressive therapy for the autoimmune disease. The following are exceptions to this criterion: * Subjects with vitiligo or alopecia * Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement * Subjects with psoriasis not requiring systemic treatment. * Subjects with history of immune-related hyperthyroidism with total thyroidectomy currently in remission * Select situations after approval of study PI * Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Has received a live vaccine within 30 days of planned start of study therapy. °Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. * Is unwilling to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study. The use of LAR for cognitively impaired patients is not permitted.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose limiting toxicities (DLTs) (Safety Run-in only) | up to 8 weeks | 6-18 patients will be enrolled during a safety run-in period to assess toxicities. (NCI Common Terminology Criteria for Adverse Events version 5.0) |
| Progression-free (PFS) | 2 years | PFS will be defined as the number of days from the date of the first dose of drug to the date of an event of disease progression/recurrence, according to RECIST criteria version 1.1 |
Countries
United States
Contacts
CONTACTYing Liu, MD, MPH
CONTACTRoisin O'Cearbhaill, MD
PRINCIPAL_INVESTIGATORYing Liu, MD, MPH
Memorial Sloan Kettering Cancer Center
Outcome results
None listed